Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
119 results about "Fatty acid synthase" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Fatty acid synthase (FAS) is an enzyme that in humans is encoded by the FASN gene. Fatty acid synthase is a multi-enzyme protein that catalyzes fatty acid synthesis. It is not a single enzyme but a whole enzymatic system composed of two identical 272 kDa multifunctional polypeptides, in which substrates are handed from one functional domain to the next.
Polyunsaturated fatty acid production in heterologous organisms using PUFA polyketide synthase systems
InactiveUS20070245431A1Improve the level ofReduce competitionOther foreign material introduction processesOxidoreductasesBiotechnologyHeterologous
Disclosed are novel acyl-CoA synthetases and novel acyltransferases, nucleic acid molecules encoding the same, recombinant nucleic acid molecules and recombinant host cells comprising such nucleic acid molecules, genetically modified organisms (microorganisms and plants) comprising the same, and methods of making and using the same. Also disclosed are genetically modified organisms (e.g., plants, microorganisms) that have been genetically modified to express a PKS-like system for the production of PUFAs (a PUFA PKS system or PUFA synthase), wherein the organisms have been modified to express an acyl-CoA synthetase, to express an acyl transferase, to delete or inactivate a fatty acid synthase (FAS) expressed by the organism, to reduce competition for malonyl CoA with the PUFA synthase or to increase the level of malonyl CoA in the plant or plant cell, and in one aspect, to inhibit KASII or KASIII. Additional modifications, and methods to make and use such organisms, in addition to PUFAs and oils obtained from such organisms, are disclosed, alone with various products including such PUFAs and oils.
Owner:SEMBIOSYS GENETICS INC +1
Novel antagonists of the human fatty acid synthase thioesterase
InactiveUS20070203236A1Inhibit tumor cell growthBiocideOrganic chemistryMetaboliteCompound (substance)
The present invention provides for compounds of formula (I)-(XIII), as well as pharmaceutically acceptable salts thereof, metabolites thereof, pro-drugs thereof, and pharmaceutical kits that include such compounds. The present invention also provides for the compounds of formula (I)-(XIII) for use in medical therapy or diagnosis. The present invention also provides for the use of the compounds of formula (I)-(XIII) in treating cancer in mammals (e.g., humans), as well inhibiting tumor cell growth in such mammals. The present invention also provides for methods of inhibiting FAS. The methods include contacting FAS with an effective amount of a compound of formula (I)-(XIII). The present invention also provides for methods of inhibiting the TE domain of the FAS. The methods include contacting the thioesterase TE domain of the FAS with an effective amount of a compound of formula (I)-(XIII). The present invention also provides for methods of treating cancer in mammals, as well as methods of inhibiting tumor cell growth in such mammals. The methods include administering a compound of formula (I)-(XIII) to a mammal in need of such treatment.
Owner:BURNHAM INST THE
Polyunsaturated fatty acid production in heterologous organisms using pufa polyketide synthase systems
ActiveUS20070270494A1Improve the level ofReduce competitionAntibacterial agentsOrganic active ingredientsHeterologousAcyl-CoA synthetase
Disclosed are novel acyl-CoA synthetases and novel acyltransferases, nucleic acid molecules encoding the same, recombinant nucleic acid molecules and recombinant host cells comprising such nucleic acid molecules, genetically modified organisms (microorganisms and plants) comprising the same, and methods of making and using the same. Also disclosed are genetically modified organisms (e.g., plants, microorganisms) that have been genetically modified to express a PKS-like system for the production of PUFAs (a PUFA PKS system or PUFA synthase), wherein the organisms have been modified to express an acyl-CoA synthetase, to express an acyl transferase, to delete or inactivate a fatty acid synthase (FAS) expressed by the organism, to reduce competition for malonyl CoA with the PUFA synthase or to increase the level of malonyl CoA in the organism, and in one aspect, to inhibit KASII or KASIII. Additional modifications, and methods to make and use such organisms, in addition to PUFAs and oils obtained from such organisms, are disclosed, alone with various products including such PUFAs and oils.
Owner:DSM IP ASSETS BV
Metabolically engineered cells for the production of polyunsaturated fatty acids
The present invention relates to the construction and engineering of cells, more particularly microorganisms for producing PUFAs with four or more double bonds from non-fatty acid substrates through heterologous expression of an oxygen requiring pathway. The invention especially involves improvement of the PUFA content in the host organism through fermentation optimization, e.g. decreasing the temperature and / or designing an optimal medium, or through improving the flux towards fatty acids by metabolic engineering, e.g. through over-expression of fatty acid synthases, over-expression of other enzymes involved in biosynthesis of the precursors for PUFAs, or codon optimization of the heterologous genes, or expression of heterologous enzymes involved in the biosynthesis of the precursor for PUFAs.
Owner:FLUXOME SCI AS
Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer
InactiveUS20090325877A1Reducing FASN activityInhibitory activityBiocidePeptide/protein ingredientsReceptor tyrosine kinase inhibitorFatty acid
A pharmaceutical combination product is disclosed that comprises a receptor tyrosine kinase inhibitor and a fatty acid synthase inhibitor, and to the use thereof in the manufacture of a medicament for use in the treatment or prophylaxis of cancer.
Owner:WYETH
Metabolically engineered Saccharomyces cells for the production of polyunsaturated fatty acids
Owner:FLUXOME SCI AS
Novel antagonists of the human fatty acid synthase thioesterase
Owner:BURNHAM INST FOR MEDICAL RES
Therapeutic Agents - 551
A compound of formula Ior a pharmaceutically acceptable salt thereof, processes for preparing such compounds, their use as Fatty Acid Synthase inhibitors, methods for their therapeutic use, particularly in the treatment of obesity, diabetes mellitus, cancer and infection and pharmaceutical compositions containing them.
Owner:ASTRAZENECA AB
Method and assay for determining FAS expression
Methods and immunoassays for the determination of fatty acid synthase (FAS) expression in patients having or suspected of having a proliferative disorder, especially prostate cancer, are disclosed. The sensitive method and assay detect the level of expression of FAS in a biological sample using antibodies that are highly specific for FAS. The method and assay can be used to monitor the progression of cancer, and / or to predict the efficacy of certain treatments or the likelihood of recurrence of the cancer.
Owner:NUCLEA BIOMARKERS
Polyunsaturated fatty acid production in heterologous organisms using pufa polyketide synthase systems
InactiveCN101573451AImprove the level ofReduce competitionMicrobiological testing/measurementAcyl Coenzyme A SynthetasesBiotechnology
Disclosed are novel acyl-CoA synthetases and novel acyltransferases, nucleic acid molecules encoding the same, recombinant nucleic acid molecules and recombinant host cells comprising such nucleic acid molecules, genetically modified organisms (microorganisms and plants) comprising the same, and methods of making and using the same. Also disclosed are genetically modified organisms (e.g., plants, microorganisms) that have been genetically modified to express a PKS-like system for the production of PUFAs (a PUFA PKS system or PUFA synthase), wherein the organisms have been modified to express an acyl-CoA synthetase, to express an acyl transferase, to delete or inactivate a fatty acid synthase (FAS) expressed by the organism, to reduce competition for malonyl CoA with the PUFA synthase or toincrease the level of malonyl CoA in the organism, and in one aspect, to inhibit KASII or KASIII. Additional modifications, and methods to make and use such organisms, in addition to PUFAs and oils o btained from such organisms, are disclosed, alone with various products including such PUFAs and oils.
Owner:DSM IP ASSETS BV
3-methoxylflavonoid compound, preparation method and application thereof
A 3-methoxy-flavone compound comprises 5,7-dihydroxy-8-(3,3-dimethyl diallyl)-3,3', 4'-trimethoxy flavone and 5, 7-2 dihydroxy-8- (3,3-dimethyl allyl)-3,4'-dimethoxy flavonoe. harmacological test results prove that: the 3-methoxy-flavone compound is an effective fatty acid synthase inhibitor, which shows the broad-spectrum anti-tumor effect in the cytotoxicity tests of various tumor cell lines and has strong tumor growth inhibiting effect on human prostate cancer cell LnCAP, human breast cancer cell ZR-75-1, human lung cancer cell NCI-H23 or human colon cancer cell HCT-116 when applied to human tumor transplant nude mice model tests. In addition, the 3-methoxy-flavone compound reveals no toxicity in mice acute toxicity tests, which then can be used as anti-tumor drug and is a new broad-spectrum anti-tumor drug with great development prospects.
Owner:殷正丰 +2
Kiwi Extract
The invention describes the preparation, isolation and use of an extract of kiwi fruit for the treatment of a disease or condition related with, caused by or mediated by activity of human pancreatic lipase and / or human fatty acid synthase.
Owner:OMNICA
Cancer-specific promoters
InactiveUS20090192101A1Improve overall utilizationShrink tumorOrganic active ingredientsTumor rejection antigen precursorsNucleotideGene product
The present invention regards cancer-specific control sequences that direct expression of a polynucleotide encoding a therapeutic gene product for treatment of the cancer. Specifically, the invention encompasses breast cancer-specific and ovarian cancer-specific control sequences. Two breast cancer-specific sequences utilize specific regions of fatty acid synthase and claudin 4 promoters, particularly in combination with a two-step transcription amplification sequence and / or a post-transcriptional control sequence. Two ovarian cancer-specific sequences utilize specific regions of hTERT and survivin promoters, particularly in combination with a two-step transcription amplification sequence and / or a post-transcriptional control sequence. In more particular embodiments, these polynucleotides are administered in combination with liposomes.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Novel Polyhydroxylated Compounds as Fatty Acid Synthase (FASN) Inhibitors
InactiveUS20100190856A1Inhibition becomes largerEasy to manageOrganic active ingredientsBiocideEnzyme inhibitorFatty Acid Synthetases
The present invention relates to new polyhydroxylated compounds and, in particular, to its activity as fatty acid synthase (FASN) inhibitors and to their use for the treatment of pathological states for which an inhibitor of this enzyme is indicated. The invention further relate to pharmaceutical compositions containing them and to a process for the preparation of such compounds.
Owner:FUNDACIO PRIVADA INST DINVESTIGACIO BIOMEDICA DE GIRONA DR JOSEP TRUETA +1
Pharmaceutical Composition Comprising Metadoxine and Garlic Oil For Preventing and Treating Alcohol-Induced Fatty Liver and Steatohepatitis
InactiveUS20100062090A1Effective treatmentPrevent hepatitisBiocideOrganic active ingredientsTG - TriglycerideMetadoxine
Provided is a pharmaceutical or food or drink composition for preventing or treating alcohol-induced fatty liver or steatohepatitis comprising metadoxine (pyridoxol 1-2-pyrrolidone-5-carboxylate) and garlic oil as active ingredients. The concurrent administration of metadoxine and garlic oil according to the present invention exhibits outstandingly superior effects of inhibiting the accumulation of triglyceride and increase of blood AST (aspartate aminotransferase) level in liver el tissue, inhibiting the expression of FAS (fatty acid synthase), CYP2E1 and iNOS (inducible nitric oxide synthase) and inhibiting the deactivation of AMPK (AMP-activated protein kinase), as compared to the administration of metadoxine or garlic oil only.
Owner:SEOUL NAT UNIV R&DB FOUND
Method for inhibiting cancer development by fatty acid synthase inhibitors
A method for inhibiting or preventing cancer development by the administration of fatty acid synthase (FAS) inhibitors. In particular, the present invention prohibits or delays the development of invasive cancer from pre-malignant (non-invasive) lesions that express FAS. Compositions containing FAS inhibitors also are provided, as well as methods for administering the FAS inhibitors and compositions to patients in need thereof.
Owner:FASGEN +1
Polyunsaturated fatty acid synthase nucleic acid molecules and polypeptides, compositions, and methods of making and uses thereof
ActiveUS8940884B2Peptide/protein ingredientsUnicellular algaeDocosahexaenoic acidEicosapentaenoic acid
Owner:DSM IP ASSETS BV
Extract of yangtao actinidia root and preparation method and applications thereof
InactiveCN101757056ADon't worry about gaining weightAppetite suppressantMetabolism disorderAntineoplastic agentsOrganic solventActinidia
The invention discloses an extract of yangtao actinidia root and a preparation method and applications thereof. The extract of yangtao actinidia root, which is provided by the invention, is prepared by the following method: using water and / or an organic solvent as an extractant to extract the extract of yangtao actinidia root from yangtao actinidia root. Experiment shows that the extract of yangtao actinidia root can effectively inhibit the activity of fatty acid synthase. The inhibition kinetic analysis shows that the inhibition of the extract of yangtao actinidia root for the fatty acid synthase and the substrates of acetylcoenzyme A and NADPH have a competitive and non-competitive mixed type relationship, but more close to the non-competitive relationship; and the inhibition of the extract of yangtao actinidia root for the fatty acid synthase and the substrate of malonyl coenzyme A have a competitive and non-competitive mixed type relationship. The extract of yangtao actinidia root can be applied to the preparation of weight-reducing medicament and the medicament for preventing and treating cancers, and also can be widely applied as food, health product and daily chemical additive.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Production of fatty acid esters
Methods of producing fatty acid esters, such as fatty acid ethyl esters, from microorganisms genetically engineered to alter the expression of genes involved in fatty acid synthesis and / or ethanol production, such that a microorganism is obtained that can produce an alcohol, a fatty acid and an ester synthase in the absence of exogenously added alcohols.
Owner:GENOMATICA INC
Heterocyclic modulators of lipid synthesis and combinations thereof
Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.
Owner:GANNEX PHARM CO LTD
Heterocyclic modulators of lipid synthesis
ActiveCN103561576AImproved antiviral activityHigh anticancer activityBiocideSenses disorderFatty acid biosynthesisMembrane lipid metabolism
Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and / or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatits C infection, cancer and metabolic disorders.
Owner:GANNEX PHARM CO LTD
Fatty acid synthase in liver disease
InactiveUS20090162870A1Improve the level ofMicrobiological testing/measurementDisease diagnosisBiologyLiver disease
Methods and compositions for detecting elevated fatty acid synthase (FAS) expression in the liver of a subject are disclosed. The detection may be of expression in liver cells per se or in a bodily fluid of a subject. Also disclosed are methods for identifying the presence or absence of liver disease or pathology in relation to elevated FAS. The disclosed methods may be practiced with various compositions comprising reagents for detecting FAS expression as described herein.
Owner:FASGEN
Preparation of fatty acid esters of glycerol formal and its use as biofuel
ActiveUS8142525B2Increase contentIncrease cetane numberOrganic chemistryFatty acid esterificationTransesterificationTriglyceride
This invention describes the preparation of fatty acid esters of glycerol formal either by a triglyceride transesterification process or, alternatively, by an esterification process of fatty acids previously obtained from the hydrolysis of triglycerides (fat splitting), with glycerol formal in the presence of an acid or basic catalyst. Also the invention describes the use of these fatty acid esters of glycerol formal prepared by said process as biofuel. In an embodiment, such biofuel is used in the preparation of other biofuels by its mixture with a product selected from a group formed by: glycerol formal, biodiesel, petrol-derived diesel, and mixtures thereof. The biofuels thus obtained are characterized to allow the complete incorporation of the glycerol obtained in the current biodiesel production process in a biodiesel fuel.
Owner:INST UNIV DE CIENCIA I TECH SA
Yeast Cell Modified to Overproduce Fatty Acid and Fatty Acid-Derived Compounds
The present invention provides for a genetically modified yeast host cell capable of producing one or more fatty acids, or fatty acid-derived compounds, or a mixture thereof, comprising: (a) increased expression of acetyl-CoA carboxylase (such as ACC1), (b) increased expression of one or more fatty acid synthases (such as FAS1 and FAS2), and (c) optionally reduced expression of one or more enzymes involved in or in the β-oxidation pathway (such as peroxisomal transporters PXA1 and PXA2, and β-oxidation enzymes POX1, POX2, and POX3).
Owner:RGT UNIV OF CALIFORNIA
Novel compounds, pharmaceutical compositions containing same, and methods of use for same
A pharmaceutical composition comprising a phamaceurtical diluent and a compound of formula IV wherein R21═H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, —CH2OR25, —C(O)R25, —CO(O)R25, —C(O)NR25R26, —CH2C(O)R25, or —CH2C(O)NHR25, where R25 and R26 are each independently H, C1-C10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing one or more halogen atoms. R22 ═—OH, —OR27, —OCH2C(O)R27, —OCH2C(O)NHR27, —OC(O)R27, —OC(O)OR27, —OC(O)NHNH—R5, or —OC(O)NR27R28, where R27 and R28 are each independently H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, and where R27 and R28 can each optionally contain halogen atoms; R23 and R24, the same or different from each other, are C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl. Methods of using such formulations for the treatment of cancer, to effect weight loss, to treat microbially-based infections, to inhibit neuropeptide-Y and / or fatty acid synthase, and to stimulate CPT-1.
Owner:FASGEN
Inhibitor of fatty acid synthase and application thereof
InactiveCN101768081AInhibit synthetase activityOrganic active ingredientsOrganic chemistryGluconic acidBULK ACTIVE INGREDIENT
The invention discloses an inhibitor of fatty acid synthase and application thereof, comprising the following active ingredients: 5 galloyl group gluconic acid, methyl gallate and quercetin-3-O-L-rhamnoside. The mass of three active ingredients in per gram of the inhibitor of fatty acid synthase are sequentially as follows: 18-20mug, 2-3mug, 1-2mug. The inhibitor of fatty acid synthase not only can be applied to preparation of weight loss drugs, preparation of anti-cancer drugs, but also can be widely applied to additives for foods, health products, as well as daily chemicals.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Compositions for enhancing the production of PPAR and/or PPAR-associated factors
InactiveUS20100222259A1Increase productionOrganic active ingredientsPeptide/protein ingredientsGlycemicD-Glucose
The present inventors focused on certain nutritional compositions known to have activity of controlling blood glucose levels. These foods were administered to rats for long periods, and real-time PCR was used to analyze the expression of genes associated with lipid metabolism in the liver and adipose tissues. As a result, the present inventors found that the expression of the PPARα gene is enhanced by these foods, and that this is accompanied by suppressed expression of fatty acid synthase and enhanced expression of a group of PPARα target genes associated with fatty acid metabolism. The present inventors also confirmed the effect of these foods in enhancing the expression of PPARγ and adiponectin, and discovered that these foods have the activity of enhancing the production of PPAR and PPAR-associated factors.
Owner:UNIVERSITY OF TOKUSHIMA +1
Novel compounds, pharmaceutical compositions containing same, and methods of use for same
InactiveCN101633650AGrowth inhibitionOrganic active ingredientsNervous disorderChemical compoundPharmaceutical Substances
The present invention relates to a new compound, pharmaceutical composition comprising the new compound and using method of the compound, the structure of the compound is disclosed in the description. The compound of the present invention has the functions of weight loss, anti-microbial and anti-cancer applications, inhibition of fatty acid synthase and neuropeptide-Y, and the stimulation of the activity of carnitine palmitoyl transferase-1.
Owner:FASGEN +1
Kiwi extract
The invention describes the preparation, isolation and use of an extract of kiwi fruit for the treatment of a disease or condition related with, caused by or mediated by activity of human pancreatic lipase and / or human fatty acid synthase.
Owner:OMNICA
Compositions and methods for producing lipids and other biomaterials from grain ethanol stillage and stillage derivatives
ActiveUS10662448B2Conducive to liquefactionIncrease ratingsFungiMicrobiological testing/measurementPhospholipidAcyl CoA dehydrogenase
Lipogenic yeasts bioengineered to overexpress genes for lipid production, and methods of use thereof. The yeasts are modified to express, constitutively express, or overexpress an acetyl-CoA carboxylase, an alpha-amylase, an ATP citrate lyase, a diacylglycerol acyltransferase, a fatty acid synthase, a glycerol kinase, a 6-phosphogluconate dehydrogenase, a glycerol-3-phosphate dehydrogenase, a malic enzyme, a fatty acyl-CoA reductase, a delta-9 acyl-CoA desaturase, a glycerol-3-phosphate acyltransferase, a lysophosphatidate acyltransferase, a glucose-6-phosphate dehydrogenase, a beta-glucosidase, a hexose transporter, a glycerol transporter, a glycoside hydrolase enzyme, an auxiliary activity family 9 enzyme, or combinations thereof. The yeasts in some cases are also modified to reduce or ablate activity of certain proteins. The methods include cultivating the yeast to convert low value soluble organic stillage byproducts into lipids suitable for biodiesel production and other higher value uses.
Owner:XYLOME CORP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com